Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Jumonji histone demethylases are therapeutic targets in small cell lung cancer

18 Aug 2024

Abstract excerpt

Small cell lung cancer (SCLC) is a recalcitrant cancer of neuroendocrine (NE) origin. Changes in therapeutic approaches against SCLC have been lacking over the decades. Here, we use preclinical models to identify a new therapeutic vulnerability in SCLC consisting of the targetable Jumonji lysine demethylase (KDM) family. We show that Jumonji demethylase inhibitors block malignant growth and that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research
Share to Lung Cancer Research Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39154123
DOI: 10.1038/s41388-024-03125-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Jumonji histone demethylases are therapeutic targets in small cell lung cancerPMID 39154123Read ↗

The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.Semantic proximity Read ↗

Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapySemantic proximity Read ↗

EED Maintains the Small Cell Lung Cancer Neuroendocrine Phenotype and Drives Lung Cancer Histological TransformationSemantic proximity Read ↗

BET Inhibitors Target the SCLC-N subtype Small Cell Lung Cancer by Blocking NEUROD1 TransactivationSemantic proximity Read ↗

Intrinsic and Acquired Drug Resistance to LSD1 Inhibitors in SCLC Occurs through a TEAD4 Driven Transcriptional StateSemantic proximity Read ↗

KDM6B Inhibition Enhances Chemotherapeutic Response in Small Cell Lung Cancer via Epigenetic Regulation of Apoptosis and FerroptosisSemantic proximity Read ↗

A comparative study of neuroendocrine heterogeneity in SCLC and NBLSemantic proximity Read ↗

Distinct Regulation of ASCL1 by the Cell Cycle and Chemotherapy in Small Cell Lung CancerSemantic proximity Read ↗

A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and NeuroblastomaSemantic proximity Read ↗

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Semantic proximity Read ↗

GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancerSemantic proximity Read ↗

PRC2 loss impairs small cell lung cancer tumorigenesis and enhances sensitivity to G9a/GLP inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.